EMA Authorised: Pemazyre (pemigatinib) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The European Medicines Agency authorised Pemazyre (pemigatinib) for cholangiocarcinoma with conditional approval and orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Status: Authorised. Therapeutic area: Cholangiocarcinoma. MAH: Incyte Biosciences Distribution B.V.. Decision date: 02/07/2025. Conditional approval. Orphan medicine